Berlin, Germany
Research view
Myasthenia gravis: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- CD19 13
- BCMA 13
- CD20 3
- PD-1 0
- CD40 0
- JAK 0
- AKT 0
- HIF-1 0
- IL-17 0
- mTOR 0
- PI3K 0
- AMPK 0
- AQP4 1
- COX-2 0
- GPX4 0
- HER2 0
- HMGB1 0
- IL-1 0
- IL-6 0
- MAPK 0
- NLRP3 0
- PD-L1 0
- PSMA 0
- SGLT2 0
- STAT3 0
- STING 0
EU-13 is a filter, not a ranking: it only narrows the list.
Toronto, Canada
Chapel Hill, United States
Tampa, United States
New Haven, United States
Milan, Italy
Oxford, United Kingdom
Ghent, Belgium
Shanghai, China
Beijing, China
Toronto, Canada
Cambridge, United States
Irvine, United States
Berlin, Germany
Shanghai, China
Changsha, China
Copenhagen, Denmark
Changsha, China
Chiba, Japan
Hanamaki, Japan
Rochester, United States
Washington, United States
Buffalo, United States
Barcelona, Spain
24 of 200+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Withdrawn
“pipeline strategy change”Registry text, quoted unchanged. Source
Suspended
A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
“Administrative”Registry text, quoted unchanged. Source
Terminated
“Sponsor Decision”Registry text, quoted unchanged. Source
Withdrawn
A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
“Legend discontinues the development of the IMP.”Registry text, quoted unchanged. Source
Terminated
Efficacy and Safety of HN2301 in Refractory Myasthenia Gravis(MG)
“Change of registrant”Registry text, quoted unchanged. Source
Terminated
Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis
“lack of enrollment”Registry text, quoted unchanged. Source
Withdrawn
Oxaloacetate in Myasthenia Gravis
“No funding”Registry text, quoted unchanged. Source
Withdrawn
An Exploratory Clinical Study of GC012F Injection for Refractory gMG
“The study stopped early, before enrolling its first participant.”Registry text, quoted unchanged. Source
Withdrawn
A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis
“Company shifted focus”Registry text, quoted unchanged. Source
Terminated
“Sponsor decided to halt development of satralizumab in generalized myasthenia gravis and discontinued further dosing with the study drug (while the OLE period was ongoing) upon reviewing the primary results (DB period).”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Characteristics and Prognostic Outcomes of Diaphragmatic Ultrasound in Myasthenia Gravis
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 9
- Mendelian Randomization Analysis 9
- Gene Expression Profiling 5
- Sequence Analysis, RNA 3
- Exome Sequencing 1
- Proteomics 8
- Metabolomics 6
- Flow Cytometry 4
- Immunohistochemistry 1
- Magnetic Resonance Imaging 10
- Machine Learning 8
- Cohort Studies 37
- Genome-Wide Association Study 10
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.